ReviewCurrent oncology (Toronto, Ont.)2019

Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.

C Owen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.